| 2024-04-25 12:42 | CC:HLS | HLS Therapeutics Inc | 4.75 | News Release200 | HLS to release fiscal Q1 2024 results May 9 |
| 2024-04-08 10:27 | CC:HLS | HLS Therapeutics Inc | 5.04 | News Release200 | HLS Therapeutics touts Vascepa for MACE reduction |
| 2024-03-14 16:06 | CC:HLS | HLS Therapeutics Inc | | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
| 2024-03-14 12:11 | CC:HLS | HLS Therapeutics Inc | 4.34 | SEDAR MD & A815 | SEDAR MD & A |
| 2024-03-14 12:11 | CC:HLS | HLS Therapeutics Inc | 4.34 | SEDAR Annual Information Form802 | SEDAR Annual Information Form |
| 2024-03-14 12:11 | CC:HLS | HLS Therapeutics Inc | 4.34 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
| 2024-03-14 10:25 | CC:HLS | HLS Therapeutics Inc | 3.99 | News Release200 | HLS Therapeutics loses $27.53M (U.S.) in fiscal 2023 |
| 2024-02-29 10:27 | CC:HLS | HLS Therapeutics Inc | 4.00 | News Release200 | HLS Therapeutics to release 2023 results March 14 |
| 2024-02-06 10:00 | CC:HLS | HLS Therapeutics Inc | 4.25 | News Release200 | HLS to list Vascepa under with B.C. drug plan |
| 2023-12-18 09:53 | CC:HLS | HLS Therapeutics Inc | 3.67 | News Release200 | HLS Therapeutics CFO Hendrickson to step down |
| 2023-11-14 17:52 | CC:HLS | HLS Therapeutics Inc | 3.73 | News Release200 | HLS study finds Vascepa lowers cardio risk in patients |
| 2023-11-10 08:23 | CC:HLS | HLS Therapeutics Inc | 4.07 | In the News525 | Globe says Keywood cuts HLS Therapeutics to "hold" |
| 2023-11-09 10:08 | CC:HLS | HLS Therapeutics Inc | 4.86 | News Release200 | HLS Therapeutics loses $6.9-million (U.S.) in Q3 2023 |
| 2023-11-09 09:38 | CC:HLS | HLS Therapeutics Inc | 4.86 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2023-11-09 09:34 | CC:HLS | HLS Therapeutics Inc | 4.86 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-10-26 11:25 | CC:HLS | HLS Therapeutics Inc | 5.01 | News Release200 | HLS Therapeutics to release Q3 2023 results Nov. 9 |
| 2023-09-20 07:22 | CC:HLS | HLS Therapeutics Inc | 4.95 | In the News525 | Globe says Keywood keeps HLS Therapeutics at "buy" |
| 2023-08-14 12:19 | CC:HLS | HLS Therapeutics Inc | 4.98 | News Release200 | HLS Therapeutics extends credit agreement to 2026 |
| 2023-08-10 10:36 | CC:HLS | HLS Therapeutics Inc | 5.90 | News Release200 | HLS Therapeutics loses $9.43-million (U.S.) in Q2 2023 |
| 2023-08-10 07:15 | CC:HLS | HLS Therapeutics Inc | 5.90 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-08-03 19:15 | CC:HLS | HLS Therapeutics Inc | 5.92 | News Release200 | HLS Therapeutics to release Q2 results Aug. 10 |
| 2023-07-04 11:05 | CC:HLS | HLS Therapeutics Inc | 5.76 | SEDAR Early Warning Report807 | SEDAR Early Warning Report |
| 2023-06-22 07:10 | CC:HLS | HLS Therapeutics Inc | 6.43 | News Release200 | HLS Therapeutics appoints Hanna to board |
| 2023-06-16 18:10 | CC:HLS | HLS Therapeutics Inc | 6.55 | News Release200 | HLS Therapeutics holders approve all matters at AGM |
| 2023-06-08 07:26 | CC:HLS | HLS Therapeutics Inc | 4.73 | News Release200 | HLS Therapeutics directors Lanthier, DeGolyer to retire |
| 2023-05-11 13:10 | CC:HLS | HLS Therapeutics Inc | 5.06 | News Release200 | HLS Therapeutics loses $5.79M in Q1, cancels dividend |
| 2023-05-11 07:23 | CC:HLS | HLS Therapeutics Inc | 5.06 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-05-11 07:23 | CC:HLS | HLS Therapeutics Inc | 5.06 | SEDAR MD & A815 | SEDAR MD & A |